Ethane

Ethane

SCHEMBL6102425

CC.CN1CCN(c2cc(C(=O)Nc3ccccc3)c3ccccc3n2)CC1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.73
HIF1A Q16665 3/20 0.73
ALDH1A1 P00352 2/20 0.68
KMT2A Q03164 2/20 0.68
USP2 O75604 2/20 0.68
MEN1 O00255 1/20 0.68
PKM P14618 1/20 0.68
MAPT P10636 4/20 0.60
TP53 P04637 2/20 0.60
RAB9A P51151 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
HTR3A P46098 2/20 0.56
HTT P42858 1/20 0.55
LMNA P02545 1/20 0.55
CYP3A4 P08684 2/20 0.54
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL6097475 0.91 KDM4E (0.77) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6099926 0.89 KDM4E (0.75) KDM4EHIF1AALDH1A1KMT2AUSP2
SCHEMBL6102421 0.89 KDM4E (0.64) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6099875 0.87 KDM4E (0.95) KDM4EHIF1AALDH1A1USP2PKM
Ethane SCHEMBL6098608 0.87 KDM4E (0.72) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6097651 0.86 KDM4E (0.71) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6099689 0.85 KDM4E (0.69) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6112027 0.84 KDM4E (0.65) KDM4EHIF1AALDH1A1KMT2AUSP2
SCHEMBL28455263 0.84 KDM4E (0.75) KDM4EHIF1AALDH1A1KMT2AUSP2
Ethane SCHEMBL6100439 0.82 KDM4E (0.65) KDM4EHIF1AALDH1A1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020156095-A1 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION 2002-10-24 US claimed
US-7041664-B2 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION (US) 2006-05-09 US disclosed
US-6894044-B2 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION (US) 2005-05-17 US disclosed
US-6369053-B1 CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES; ALSO USEFUL AS PROBES FOR THE LOCALIZATION OF CELL SURFACE RECEPTORS; NONPEPTIDE NK-3 RECEPTOR ANTAGONISTS NEUROGEN CORPORATION 2002-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156095-A1 2-aminoquinolinecarboxamides: neurokinin receptor ligands KCNQ3, OPRK1, KCNQ1 KDM4E 2712/4885HIF1A 3061/4885ALDH1A1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.